{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:17:53Z","timestamp":1765610273687,"version":"build-2065373602"},"reference-count":75,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.beha.2022.101374","type":"journal-article","created":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T17:34:20Z","timestamp":1660498460000},"page":"101374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Myeloproliferative neoplasms in adolescents and young adults"],"prefix":"10.1016","volume":"35","author":[{"given":"Rodothea","family":"Amerikanou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samah","family":"Alimam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2022.101374_bib1","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1182\/blood-2016-10-696005","article-title":"Myeloproliferative neoplasm stem cells","volume":"129","author":"Mead","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.beha.2022.101374_bib2","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1200\/JCO.2016.70.7968","article-title":"Genomics of myeloproliferative neoplasms","volume":"35","author":"Zoi","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2022.101374_bib3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/sj.thj.6200368","article-title":"Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia","volume":"5","author":"Michiels","year":"2004","journal-title":"Hematol J"},{"key":"10.1016\/j.beha.2022.101374_bib4","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/bjh.17848","article-title":"Revisiting Diagnostic performances of serum erythropo\u00efetin level and JAK2 mutation for polycythemias: analysis of a cohort of 1090 patients with red cell mass measurement","volume":"196","author":"Maslah","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2022.101374_bib5","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/ajcp\/aqac016","article-title":"How I diagnose primary myelofibrosis","volume":"157","author":"Prakash","year":"2022","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.beha.2022.101374_bib6","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ajh.26008","article-title":"Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management","volume":"95","author":"Tefferi","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2022.101374_bib7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ajh.26050","article-title":"Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management","volume":"96","author":"Tefferi","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2022.101374_bib8","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ejh.12256","article-title":"Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union","volume":"92","author":"Moulard","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.beha.2022.101374_bib9","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1002\/ajh.25270","article-title":"Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger","volume":"93","author":"Szuber","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2022.101374_bib10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00277-017-3165-9","article-title":"Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"97","author":"Boddu","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.beha.2022.101374_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100096","article-title":"Adolescents and young adults (AYA) with cancer: a position paper from the AYA working group of the European society for medical oncology (ESMO) and the European society for paediatric oncology (SIOPE)","volume":"6","author":"Ferrari","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.beha.2022.101374_bib12","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/joim.13019","article-title":"Incidence of myeloproliferative neoplasms \u2013 trends by subgroup and age in a population-based study in Sweden","volume":"287","author":"Hultcrantz","year":"2020","journal-title":"J Intern Med"},{"key":"10.1016\/j.beha.2022.101374_bib13","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/leu.2012.12","article-title":"How to manage children and young adults with myeloproliferative neoplasms","volume":"26","author":"Barbui","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2022.101374_bib14","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2022007201","article-title":"Real world study of children and young adults with myeloproliferative neoplasms identifying risks and unmet needs","author":"Sobas","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2022.101374_bib15","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.3324\/haematol.2018.200832","article-title":"Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review","volume":"104","author":"Ianotto","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2022.101374_bib16","doi-asserted-by":"crossref","DOI":"10.3109\/10428194.2012.759656","article-title":"Age-related differences in disease characteristics and clinical outcomes in polycythemia vera","volume":"54","author":"Stein","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2022.101374_bib17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","article-title":"The myeloproliferative neoplasm symptom assessment form (MPN-SAF): international prospective validation and reliability trial in 402 patients","volume":"118","author":"Scherber","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2022.101374_bib18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1001\/archinte.1989.00390010109013","article-title":"Erythromelalgia and myeloproliferative disorders","volume":"149","author":"Kurzrock","year":"1989","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.beha.2022.101374_bib19","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/j.1365-2362.2010.02334.x","article-title":"Polycythemia vera-associated pruritus and its management","volume":"40","author":"Saini","year":"2010","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.beha.2022.101374_bib20","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/ejh.13232","article-title":"Characteristics and outcomes of young adults with Philadelphia-negative myeloproliferative neoplasms","volume":"102","author":"Barzilai","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.beha.2022.101374_bib21","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.3390\/ijms23063206","article-title":"Thromboinflammation in myeloproliferative neoplasms (MPN);A puzzle still to Be solved","volume":"23","author":"Bhuria","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.beha.2022.101374_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.tru.2021.100081","article-title":"Thrombosis in myeloproliferative neoplasms: a clinical and pathophysiological perspective","volume":"5","author":"Kelliher","year":"2021","journal-title":"Thrombosis Update"},{"key":"10.1016\/j.beha.2022.101374_bib23","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/leu.2015.87","article-title":"Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis","volume":"29","author":"Palandri","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2022.101374_bib24","doi-asserted-by":"crossref","first-page":"5617","DOI":"10.1182\/blood-2008-12-196014","article-title":"JAK2V617F mutation for the early diagnosis of Ph\u2212 myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis","volume":"113","author":"Dentali","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2022.101374_bib25","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/bjh.13080","article-title":"A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera","volume":"167","author":"Lussana","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2022.101374_bib26","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3324\/haematol.12053","article-title":"Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments","volume":"93","author":"de Stefano","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2022.101374_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-018-0100-9","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018","volume":"8","author":"Finazzi","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.beha.2022.101374_bib28","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/ajh.26067","article-title":"Myeloproliferative neoplasms and pregnancy: overview and practice recommendations","volume":"96","author":"Gangat","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2022.101374_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-019-0166-y","article-title":"Targeted therapies for myeloproliferative neoplasms","volume":"7","author":"Li","year":"2019","journal-title":"Biomark Res"},{"key":"10.1016\/j.beha.2022.101374_bib30","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood-2017-06-782037","article-title":"Myeloproliferative neoplasms: from origins to outcomes","volume":"30","author":"Nangalia","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.beha.2022.101374_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01116-z","article-title":"Molecular pathogenesis of the myeloproliferative neoplasms","volume":"14","author":"Greenfield","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"9","key":"10.1016\/j.beha.2022.101374_bib32","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2022.101374_bib33","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N Engl J Med"},{"year":"2008","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","key":"10.1016\/j.beha.2022.101374_bib34"},{"key":"10.1016\/j.beha.2022.101374_bib35","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1182\/blood-2014-05-577635","article-title":"Therapy for myeloproliferative neoplasms: when, which agent, and how?","volume":"124","author":"Geyer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2022.101374_bib36","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/bjh.15648","article-title":"A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline","volume":"184","author":"McMullin","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2022.101374_bib37","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2141.2010.08122.x","article-title":"Guideline for investigation and management of adults and children presenting with a thrombocytosis","volume":"149","author":"Harrison","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2022.101374_bib38","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2022.101374_bib39","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.6004\/jnccn.2017.0157","article-title":"NCCN guidelines insights: myeloproliferative neoplasms, version 2.2018","volume":"15","author":"Mesa","year":"2017","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.beha.2022.101374_bib40","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/S2352-3026(22)00046-1","article-title":"Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations","volume":"9","author":"Marchetti","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.beha.2022.101374_bib41","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11899-020-00571-8","article-title":"Myeloproliferative neoplasms in children, adolescents, and young adults","volume":"15","author":"Kucine","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.beha.2022.101374_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12574","article-title":"Thrombosis in myeloproliferative neoplasms: treatment outcomes of direct oral anticoagulants and vitamin K antagonists","volume":"5","author":"Fedorov","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.beha.2022.101374_bib43","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40164-017-0090-5","article-title":"Histomorphological responses after therapy with pegylated interferon \u03b1-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)","volume":"6","author":"Masarova","year":"2017","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.beha.2022.101374_bib44","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2022.101374_bib45","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2006-03-009860","article-title":"High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a","volume":"108","author":"Kiladjian","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2022.101374_bib46","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3324\/haematol.2017.181297","article-title":"Benefits and pitfalls of pegylated interferon-\u03b12a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study","volume":"103","author":"Ianotto","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2022.101374_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28888","article-title":"Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia","volume":"68","author":"Kucine","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.beha.2022.101374_bib48","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-021-04527-7","article-title":"Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms","author":"Choi","year":"2021","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.beha.2022.101374_bib49","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11096-005-1319-7","article-title":"Side effects of interferon-\u03b1 therapy","volume":"27","author":"Sleijfer","year":"2005","journal-title":"Pharm World Sci"},{"key":"10.1016\/j.beha.2022.101374_bib50","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.3324\/haematol.2011.061390","article-title":"Experience with pegylated interferon \u03b1-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients","volume":"97","author":"Gowin","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2022.101374_bib51","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2017.015","article-title":"Hydroxycarbamine: from an old drug used in malignant hemopathies to a current standard in sickle cell disease","volume":"9","author":"Cannas","year":"2017","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.beha.2022.101374_bib52","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/bjh.15235","article-title":"Guidelines for the use of hydroxycarbamide in children and adults with sickle cell disease","volume":"181","author":"Qureshi","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2022.101374_bib53","first-page":"1046","article-title":"Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia","volume":"101","author":"Ballas","year":"2009","journal-title":"J Natl Med Assoc"},{"key":"10.1016\/j.beha.2022.101374_bib54","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1182\/blood-2010-08-270033","article-title":"How I treat essential thrombocythemia","volume":"117","author":"Beer","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2022.101374_bib55","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.2008.20.3174","article-title":"Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy","volume":"27","author":"Campbell","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2022.101374_bib56","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2022.101374_bib57","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/bjh.13605","article-title":"How we diagnose and treat essential thrombocythaemia","volume":"171","author":"Alimam","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2022.101374_bib58","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/1534735416661417","article-title":"Physical activity as a nonpharmacological symptom management approach in myeloproliferative neoplasms: recommendations for future research","volume":"16","author":"Eckert","year":"2017","journal-title":"Integr Cancer Ther"},{"issue":"3","key":"10.1016\/j.beha.2022.101374_bib59","doi-asserted-by":"crossref","DOI":"10.2196\/33581","article-title":"Mobile app intervention on reducing the myeloproliferative neoplasm symptom burden: pilot feasibility and acceptability study","volume":"6","author":"Win","year":"2022","journal-title":"JMIR Form Res"},{"key":"10.1016\/j.beha.2022.101374_bib60","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1365-2141.1987.00285.x","article-title":"Polycythaemia vera in young people: an analysis of 58 cases diagnosed before 40 years","volume":"67","author":"Najean","year":"1987","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2022.101374_bib61","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0002-9343(90)90491-U","article-title":"Hemostatic complications in young patients with essential thrombocythemia","volume":"88","author":"Mitus","year":"1990","journal-title":"Am J Med"},{"key":"10.1016\/j.beha.2022.101374_bib62","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1159\/000512929","article-title":"Accelerated phase of myeloproliferative neoplasms","volume":"144","author":"Shahin","year":"2021","journal-title":"Acta Haematol"},{"key":"10.1016\/j.beha.2022.101374_bib63","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/bjh.14289","article-title":"Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study","volume":"175","author":"Alimam","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2022.101374_bib64","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.12666","article-title":"Association of treatments for myeloproliferative neoplasms during pregnancy with birth rates and maternal outcomes: a systematic review and meta-analysis","volume":"2","author":"Maze","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.beha.2022.101374_bib65","first-page":"1477","article-title":"The management and outcome of 18 pregnancies in women with polycythemia vera","volume":"90","author":"Robinson","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2022.101374_bib66","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/01485010490474823","article-title":"Interferon alpha-2b may impair testicular histology including spermatogenesis in a rat model","volume":"50","author":"Ulusoy","year":"2004","journal-title":"Arch Androl"},{"key":"10.1016\/j.beha.2022.101374_bib67","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1677\/joe.1.06007","article-title":"Sexual dysfunction in males with chronic hepatitis C and antiviral therapy: interferon-induced functional androgen deficiency or depression?","volume":"185","author":"Kraus","year":"2005","journal-title":"J Endocrinol"},{"key":"10.1016\/j.beha.2022.101374_bib68","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3390\/ijerph6031124","article-title":"Adverse effects of a clinically relevant dose of hydroxyurea used for the treatment of sickle cell disease on male fertility endpoints","volume":"6","author":"Jones","year":"2009","journal-title":"Int J Environ Res Publ Health"},{"key":"10.1016\/j.beha.2022.101374_bib69","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1006\/taap.1998.8593","article-title":"Involvement of germ cell apoptosis in the induction of testicular toxicity following hydroxyurea treatment","volume":"155","author":"Shin","year":"1999","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.beha.2022.101374_bib70","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ajh.23635","article-title":"Pregnancy complications predict thrombotic events in young women with essential thrombocythemia","volume":"89","author":"Randi","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2022.101374_bib71","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bjh.16453","article-title":"How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy","volume":"189","author":"Robinson","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2022.101374_bib72","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.3324\/haematol.2015.131458","article-title":"Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia","volume":"100","author":"Rumi","year":"2015","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.beha.2022.101374_bib73","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s00432-020-03430-4","article-title":"Interferon alpha for essential thrombocythemia during 34 high-risk pregnancies: outcome and safety","volume":"147","author":"Schrickel","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.beha.2022.101374_bib75","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1080\/17474086.2018.1506325","article-title":"Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy","volume":"11","author":"Griesshammer","year":"2018","journal-title":"Expet Rev Hematol"},{"key":"10.1016\/j.beha.2022.101374_bib77","doi-asserted-by":"crossref","first-page":"9445","DOI":"10.1002\/cam4.3566","article-title":"The SIMM study: survey of integrative medicine in myeloproliferative neoplasms","volume":"9","author":"Gowin","year":"2020","journal-title":"Cancer Med"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692622000299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692622000299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:07:51Z","timestamp":1761498471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692622000299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1521692622000299"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2022.101374","relation":{},"ISSN":["1521-6926"],"issn-type":[{"type":"print","value":"1521-6926"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myeloproliferative neoplasms in adolescents and young adults","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2022.101374","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101374"}}